A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Combretastatin A1 (OXi4503) is a dual-function drug with vascular disrupting and cytotoxic properties that has exhibited single-agent anti-leukemia activity in murine xenograft models of acute myeloid leukemia (AML) and in a prior Phase 1A clinical study for relapsed/refractory (R/R) AML. The purpos...

Descripción completa

Detalles Bibliográficos
Autores principales: Uckun, Fatih M., Cogle, Christopher R., Lin, Tara L., Qazi, Sanjive, Trieu, Vuong N., Schiller, Gary, Watts, Justin M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016810/
https://www.ncbi.nlm.nih.gov/pubmed/31888052
http://dx.doi.org/10.3390/cancers12010074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016810/
https://www.ncbi.nlm.nih.gov/pubmed/31888052
http://dx.doi.org/10.3390/cancers12010074

Ejemplares similares